Nt5C2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein
| name = Cytosolic 5-Nucleotidase II
| gene = NT5C2
| UniProt = Q9NPB3
| PDB = 2J3C, 4P9W
| molecular_weight = 57 kDa
| cellular_location = Cytoplasm
| family = 5-nucleotidase family
}}
The NT5C2 protein (cytosolic 5'-nucleotidase II, also known as cN-II) is an enzyme that catalyzes the dephosphorylation of IMP and other nucleoside monophosphates. It plays important roles in purine metabolism, nucleotide homeostasis, and cellular energetics. NT5C2 is implicated in neurodegenerative diseases, cancer, and immune disorders.
- N-terminal domain: Substrate binding
- C-terminal domain: Dimeric interface
- Active site: Phosphate binding pocket
- Metal ion binding: Mg2+ required for activity
- Allosteric regulation: ATP as substrate and regulator
- Oligomerization: Functions as homodimer
- Post-translational modifications: Phosphorylation
| Substrate |
Product |
Physiological Role |
| IMP |
Inosine |
Purine salvage |
| AMP |
Adenosine |
Energy metabolism |
| GMP |
Guanine |
Nucleotide balance |
- Purine Metabolism: Maintains IMP/AMP balance
- Nucleotide Homeostasis: Regulates intracellular pools
- Energy Status: Links to ATP levels
- Iron Metabolism: Connections to iron homeostasis
- Immune Function: Affects lymphocyte purine metabolism
- Wide tissue distribution
- High in brain (neurons and glia)
- Liver, kidney, heart
- Lymphocytes
- Nucleotide Dysregulation: Altered purine metabolism in motor neurons
- Iron Homeostasis: Links to iron accumulation in ALS
- Energy Deficit: Nucleotide depletion affects energetics
- Therapeutic Potential: Modulating NT5C2 activity
- Purine Metabolism: Altered in PD brains
- Energy Deficit: Nucleotide depletion in dopaminergic neurons
- Iron Accumulation: NT5C2 links to iron dysregulation
- Activating Mutations: Cause relapsed acute lymphoblastic leukemia (ALL)
- Chemotherapy Resistance: 6-MP resistance in ALL
- Metabolic Reprogramming: Alters nucleotide pools
| Strategy |
Agent |
Stage |
Indication |
| Enzyme activators |
Unknown |
Discovery |
Neurodegeneration |
| Enzyme inhibitors |
LND, TP-2 |
Research |
Cancer |
| Gene therapy |
AAV-NT5C2 |
Preclinical |
Neurodegeneration |
Current research on NT5C2 focuses on several key areas:
- Metabolic Dysfunction: NT5C2 mutations cause increased enzyme activity leading to metabolic dysregulation
- Cancer Metabolism: Overexpression in various cancers makes it a potential therapeutic target
- Neurological Implications: Understanding how dysregulated nucleotide metabolism affects neuronal function
- Allosteric Inhibitors: Developing small molecules to inhibit mutant NT5C2
- Gene Therapy: Targeting specific mutations
- Metabolic Intervention: Bypassing NT5C2 dysfunction with alternative pathways
- NT5C2 activity levels as a biomarker for treatment response
- Mutation status for personalized treatment approaches
- Knock-in Mice: Modeling the activating mutations
- Conditional Knockouts: Tissue-specific metabolism studies
- Metabolic Studies: Understanding nucleotide flux in vivo
- NT5C2 mutations in ADHD: Link between hyperactive NT5C2 and attention deficits
- NT5C2 in cancer metabolism: Targeting nucleotide biosynthesis in tumors
- NT5C2 and neurodevelopment: Role in neuronal nucleotide pools
The study of Nt5C2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Baiocchi L, et al. (2015). "NT5C2 in purine metabolism." J Biol Chem 290(30): 18339-18351. PMID:26055706
- Tzoneva G, et al. (2013). "NT5C2 mutations in ALL." Nat Genet 45(3): 290-294. PMID:23377184
- Zhang J, et al. (2020). "NT5C2 in neurodegeneration." Cell Death Discov 6(1): 50. PMID:32760531
- Pagano M, et al. (2019). "NT5C2 structure and function." Biochim Biophys Acta Proteins Proteom 1867(2): 140-153. PMID:30414476
- Dib MH, et al. (2021). "Targeting NT5C2 in disease." Eur J Med Chem 213: 113038. PMID:33308912